InMed Pharmaceuticals announces completed enrollment in phase 1 clinical trial of INM-755 CBN Cream in healthy subjects

This article was originally published here

INM-755 is a CBN cream intended as a topical therapy to treat epidermolysis bullosa (EB) and potentially other dermatological diseases. InMed has conducted preclinical pharmacology studies that suggest

The post InMed Pharmaceuticals announces completed enrollment in phase 1 clinical trial of INM-755 CBN Cream in healthy subjects appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply